Autolus Therapeutics Plc (AUTL)
2.24
-0.07
(-3.03%)
USD |
NASDAQ |
Sep 02, 16:00
2.23
-0.01
(-0.45%)
After-Hours: 18:10
Autolus Therapeutics Cash from Investing (Quarterly) : 68.03M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 68.03M |
| March 31, 2026 | 95.99M |
| December 31, 2025 | 86.65M |
| September 30, 2025 | 35.49M |
| June 30, 2025 | 96.23M |
| March 31, 2025 | -59.55M |
| December 31, 2024 | -383.59M |
| September 30, 2024 | -9.589M |
| June 30, 2024 | -0.841M |
| March 31, 2024 | -0.533M |
| December 31, 2023 | -1.477M |
| September 30, 2023 | -1.469M |
| June 30, 2023 | -4.407M |
| March 31, 2023 | -3.655M |
| December 31, 2022 | -0.6263M |
| Date | Value |
|---|---|
| September 30, 2022 | -6.797M |
| June 30, 2022 | -2.64M |
| March 31, 2022 | -0.771M |
| December 31, 2021 | -1.585M |
| September 30, 2021 | -3.861M |
| June 30, 2021 | -1.511M |
| March 31, 2021 | -1.90M |
| December 31, 2020 | -5.472M |
| September 30, 2020 | -4.049M |
| June 30, 2020 | -2.523M |
| March 31, 2020 | -2.637M |
| December 31, 2019 | -1.914M |
| September 30, 2019 | -3.781M |
| June 30, 2019 | -5.644M |
| March 31, 2019 | -7.329M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Bicycle Therapeutics Plc | -0.266M |
| Biodexa Pharmaceuticals Plc | -- |
| argenx SE | -- |
| NuCana Plc | -0.0453M |
| Mereo BioPharma Group Plc | -0.0004M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -25.16M |
| Cash from Financing (Quarterly) | -2.144M |
| Free Cash Flow | -240.12M |
| Free Cash Flow Per Share (Quarterly) | -0.098 |
| Free Cash Flow to Equity (Quarterly) | -24.77M |
| Free Cash Flow to Firm (Quarterly) | -26.08M |
| Free Cash Flow Yield | -40.28% |